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1. INTRODUCTION 
  The symptoms and signs of what we now know to be Rheumatoid arthritis was 
first noticed by Augustin Jacob Landré-Beauvais in the year 1800
1
. An US data states 
that in 1995-2007, 41 per 1, 00,000 people were diagnosed with RA each year. From 
1995 to 2007, rates increased by 2.5% each year among women
2
. The incidence of RA 
is 30 cases per 10,000 populations. This disease condition leads to premature mortality, 
disability and compromised quality of life in the industrialized and developing world.
3 
 Rheumatoid arthritis is an autoimmune disease characterized by inflammation of 
lining of joints and it affects globally about 1-2 % of the population
4
. Numerous anti-
rheumatic drugs like NSAID (Nonsteroidal anti-inflammatory drugs), DMARD 
(Disease-modifying anti-rheumatic drugs), Tumor necrosis factor alpha (TNF-α) 
inhibitors, corticosteroids, etc., have been developed and used in management of 
arthritis over past two decades.
5
 But their application in the clinic is limited because 
prolonged usage of these drugs may lead to some side effects such as peptic ulcer and 
bleeding, depression, bone marrow suppression, diarrhea, edema, dizziness, and renal 
insufficiency etc
6
., National economy was badly affected due to this disease problem as 
the young aged people are mostly affected and the patients are gradually affected both 
physically and mentally because of the worse prognosis of this disease.  So now a days 
it draws a major attention of different research scholars to find out potential therapeutic 
agent to cure arthritis.
7 
 In recent years the consumption of plant-based medicines and other botanicals in 
the west has increased. According to an estimate of World Health Organization (WHO) 
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nearly 80% of populations of developing countries rely on traditional medicines.
8 
Historically, herbal medicines have played a significant role in the management of both 
minor and major medical illnesses Even now, physicians made use of many drugs that 
possess botanical origins. Huxtable states that one-quarter of the prescriptions currently 
written in the United States are for plant products, while one quarter  is for agents based 
on botanical compounds.
9
 Some major advantages of herbal medicines are, they have 
better patient tolerance as well as acceptance. Usages of herbal medicines is highly 
economical and are more effective than synthetic drugs. Throughout the world herbal 
medicines have provided large number of most potent medicines to the modern medical 
science, both in crude form as well as a pure chemical upon which modern medicines 
are constructed and thus the therapeutic potential of herbal medicines cannot be 
ignored.
10 
 Ayurveda is an ancient scientific medical knowledge in the world. According to 
ayurveda health is the maintenance of balance of the forces in the body. When this 
balance gets disturbed the body becomes diseased. In Ayurveda Rheumatoid arthritis is 
described as ―Amavata‖, where Ama (biotoxin) as well as Vata (biophysical force) 
plays a predominant role in the samprapti (pathogenesis) of the disease. The word 
‗Ama‘ exactly means, undigested, toxic or unwholesome product, which is produced in 
the body due to weakening of digestive fire. This ‗Ama‘ will exist locally at GIT level 
or systemically in circulation or in tissues. Ama because of its heavier molecules, 
whenever present in the system it inherently obstructs the micro-channels and 
membrane system and it acts like a foreign body and hence is antigenic in nature 
leading to auto-immune reaction
8
. Now a days Ayurvedic treatment has become more 
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preferable in treatment of Rheumatoid arthritis because of its beneficial effects. So 
many Ayurvedic medicines had been described in the Ayurvedic classical books for the 
treatment of Amavata (Rheumatoid arthritis). Recent study on Ayurvedic treatment for 
RA patient using internal herbal medicines for period of one year shown a positive 
effect without evidence of organ toxicities
11
. Current study aims at evaluating anti 
arthritic activiy of classical ayurvedic formulation Nimbadi churna. 
 Free radical can be defined as an atom or a molecule that has one or more 
unpaired electrons in its valance shell and is capable of existing independently. It has an 
odd number of electrons which makes it unstable and highly reactive. Normally, it 
attacks the nearest stable molecule ―stealing‖ its electron so that it also get converted 
into a free radical .These free radicals/reactive oxygen species are produced mainly 
from two important sources  in the biological system (i) Cellular metabolism like 
mitochondrial electron transport chain, endoplasmic reticulum oxidation, NADPH 
oxidase etc., (ii) Environmental sources like drugs, pesticides,smoking , alcohol intake, 
radiations etc.
12 
 Normally, there will be an equilibrium between a free radical formation and 
endogenous antioxidant defense mechanisms, but if this balance is disturbed, it results 
in oxidative stress lead to injury of all the important cellular components like proteins, 
membrane lipids and DNA which can cause cell death.
12 
  Antioxidants are exogenous or endogenous compounds which either prevent the 
generation of toxic oxidants that are generated ,inactivate them and thereby block the 
propagation of chain reaction produced by these oxidants. These can be classified as 
enzymatic antioxidants which includes superoxide dismutase, catalase, glutathione 
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peroxidase, glutathione reductase & non-enzymatic antioxidants like nutrient 
antioxidants, beta-carotene etc., Study of  (Karatas F et al.,)
 
provide evidences for the 
involvement of free radical in the pathogenesis of rheumatoid arthritis. His study 
showed that increased oxidative stress and/or defective antioxidant status contribute to 
the pathology of rheumatoid arthritis apart from that Free radicals have also been 
implicated in causation of various diseases such as diabetes, inflammation, cancer, 
neurodegenerative disorders, atherosclerosis, liver cirrhosis, nephrotoxicity etc.
13
  
  It has been suggested that fruits, vegetables, plants are the main source of 
antioxidant in the diet. In recent days interest has been increased considerably in finding 
natural occurring antioxidants to replace synthetic antioxidants, as synthetic 
antioxidants may results in serious adverse reactions like carcinogenicity. The 
ingredients present in Nimbadi churna have been reported to possess antioxidant 
activity
14-24
. But there is no scientific proof to support antioxidant potential of Nimbadi 
churna. The present study therefore aims in investigating the antioxidant potential of 
Nimbadi churna. 
  This study attempts to validate the anti- arthritic and anti-oxidant activity of 
classical Ayurvedic formulation Nimbadi churna. 
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2. AIM AND OBJECTIVE OF THE STUDY 
 Nimbadi churna is a polyherbal ayurvedic formulation and is marketed mainly 
for the treatment of skin infections, psoriasis
25
. 
 Literature review indicates that no specific study has been carried out to evaluate 
the anti-arthritic and anti-oxidant property of nimbadi churna. Some of the ingredients 
used in nimbadi churna have been tested for their anti-arthritic
34-43
 and                         
anti oxidant
14-24 
property.So the current study aims to scentifically evaluate anti-arthritic 
activity of Nimbadi churna. 
The aim of this study is  
 Standardization of Nimbadi churna according to ayurvedic text. 
 Qualitative estimation of phytoconstituents present in Nimbadi churna. 
 Evaluation of in-vitro anti-oxidant potential of Nimbadi churna by DPPH assay. 
 Evaluation of in-vivo anti-arthritic potential of Nimbadi churna using complete 
Freund‘s adjuvant induced arthritic rats. 
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3. REVIEW OF LITERATURE 
3.1 DISEASE PROFILE 
3.1.1 Arthritis  
  The word "arthritis" commonly refers to "joint inflammation." Arthritis affects 
in and around all the joints in body, such as hip, knee, wrist, finger etc. Inflammation is 
one of the body's natural reactions to disease or injury. Inflammation may lead to Pain, 
stiffness, and swelling. Some major types of arthritis include osteoarthritis, rheumatoid 
arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile arthritis., etc. Arthritis can 
cause loss of movement in some patients and limits various day-to-day activities such as 
walking, dressing etc., Arthritis can affect individuals in any age but is more 
predominant between 25 to 50 years of age.
26
  
Fig.1 :   Normal and Arthritic Joints 
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3.1.2 Rheumatoid Arthritis 
  Rheumatoid arthritis is a most remarkable problem in the society in modern era. 
It is the second most common type of arthritis that mainly causes pain, swelling, 
stiffness and loss of function particularly in joints. It can affect any joint but it 
principally affects the wrist and fingers. The  prevalence of rheumatoid arthritis in 
indian population is around 5%.Women are more likely to suffer from rheumatoid 
arthritis when compared with men. In patients with rheumatoid arthritis, chronic 
inflammation results in synovial proliferation, destruction of bone and ligaments, finally 
lead to deformity of joints.
27 
3.1.3 Pathophysiology of Rheumatoid Arthritis  
Fig.2 : Pathophysiology of Rheumatoid Arthritis 
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  Rheumatoid arthritis is an autoimmune disease which means the body‘s immune 
system mistakenly attack on healthy tissues. The initial triggers for this disease are still 
unclear but genetics, hormones, environmental factors may all play a role
28
. The 
pathogenesis and etiology of rheumatoid arthritis are also not fully understood so far, 
but it seems likely that an autoimmune-mediated attack on joints plays a crucial role 
lead to inflammation and bone destruction. Once the initial immune response is 
triggered, cells of the immune system produce autoantibodies and inflammatory 
cytokines, creating a cascade of inflammation resulting in the formation of pannus 
which lead to destruction of cartilage and bone. Additional joint damage and systemic 
complications ensue, resulting from a complex process of inflammatory mediators 
being released in the affected joint. Immune complexes composed of IgM activate 
complement and release cytokines (like interleukin-1 (IL-1) and tumor necrosis factor 
alpha (TNF-alpha) that produce pain, joint swelling and joint damage.  Inflammatory 
cells secrete lysosomal enzymes which damage cartilage and erode bone, while PGs 
produced in the process cause vasodilatation and pain. Inflammation and synovial 
hyperplasia leading to destruction of cartilage and bone. Recent discoveries shows the 
presence of novel cytokines like IL-17, IL-18 and RANK ligand (RANKL) in the 
pathogenesis of chronic arthritis. 
 Many factors influence the risk of developing rheumatoid arthritis. The risk of 
developing this disease gets doubled with a first degree relative who has Rheumatoid 
arthritis. There is also a hormonal relationship; RA is more common in females, and 
there are high rates of disease onset associated with pregnancy. Environmental 
stressors, especially smoking and chemical exposure is thought to drive the processes 
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that induce autoimmune reactions leading up to the inflammation seen in RA. Research 
estimates that a history of smoking can increase the relative risk of RA onset more than 
2-fold, especially in individuals who are positive for anti-citrullinated protein antibodies 
(ACPA) or anti-cyclic citrullinated protein antibodies (anti-CCP); smoking is the 
strongest risk factor associated with RA
28
. 
  Different stages of RA include (i) Autoimmune priming (ii) Tissue attack 
and (iii) Chronic inflammation. The hallmark of autoimmune priming is the appearance 
of RA-associated autoantibodies like Rheumatoid factor  and/or ACPA. Both RF and 
ACPA can appear several years before the clinical onset of RA. At this stage, elevated 
serum biomarkers of inflammation also be detected, including pro-inflammatory 
cytokines. The second stage is the appearance of clinical arthritis due to a level of joint 
inflammation that is sufficient to generate clinical symptoms and signs. Synovitis is the 
hallmark of clinical RA. The third stage of RA is chronic inflammation which shows 
destruction of cartilage, bone, and other structures like tendons and ligaments results in 
deformities that may require surgical intervention.
29 
3.1.4 Diagnosing Rheumatoid Arthritis
30 
 Morning stiffness lasting >30 minutes which typically improves with movement. 
 Positive rheumatoid factor (RF value) 
 Presence of anti-CCP antibodies. 
 Radiographic evidence of bony erosions. 
 Presence of Rheumatoid nodules 
 Swan neck deformity of fingers 
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3.1.5 Treatment for Rheumatoid Arthritis
 
 The main objective of treatment aims at slowing the progression of disease and to 
provide symptomatic relief. Treatments include 
 
A) NSAIDs (Non-steroidal anti-inflammatory drugs) 
31 
 These are the first line drugs in treatment for rheumatoid arthritis and provide 
symptomatic relief from pain, swelling, immobility etc. Even though older NSAIDs 
(Non Selective COX inhibitors) such as indomethacin, sulindac, ibuprofen, diclofenac 
and naproxen have good anti-inflammatory property it‘s usage is limited because of 
numerous side effects like gastric ulcer and bleeding etc., whereas on the other hand 
newer NSAIDs (Selective COX 2 inhibitors) such as celecoxib and rofecoxib were 
believed to produce less gastric bleeding, but was found to have high risk of heart 
disease (Rofecoxib was withdrawn from market in 2004 and Valdecoxib in 2005)
25 
B) Disease-modifying anti-rheumatic drugs (DMARDs)
31 
Immunosuppressant drugs 
 Immunosuppressants inhibit both cellular and humoral immune response. These 
drugs are majorly used in treating autoimmune diseases and in organ transplantation. 
Among immunosuppressant methotrexate and azathioprine are most commonly used in 
treatment of rheumatoid arthritis whereas other immunosuppressants like 
chlorambrucil,cyclosporine, cyclophosphamide are rarely used . Methotrexate is a 
dihydrofolate reductase inhibitor and has prominent immunosuppressant and anti-
inflammatory action. Beneficial effects may probably due to inhibition of cytokine 
production, cell-mediated immune reaction and chemotaxis. Methotrexate has been now 
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become the DMARD of first choice and also used in juvenile rheumatoid arthritis. Low 
dose of Methotrexate regimen may cause oral ulceration , gastro intestinal upset etc. 
Whereas prolonged therapy results in progressive liver damage which may lead to 
cirrhosis .It is contraindicated in pregnancy, liver disease, peptic ulcer, leucopenia. 
  Azathioprine is a purine antimetabolite drug which gets converted to 6-
mercaptopurine(active metabolite) by  thiopurine methyl transferase. It potentially 
suppress cell-mediated immunity and function of natural killer cell and T-cell. It is less 
commonly used and mostly given with corticosteroids because of its steroid sparing 
effect, but azathioprine will never be combined with methotrexate. 
Antimalarial Drugs 
 Antimalarial drugs like chloroquine and hydroxychloroquine can be used to treat 
Rheumatoid arthritis. These drugs bring improvement in average of 50% patients, 
within duration of 3-6 months of treatment. Their main advantage is of relatively low 
toxicity, but it will never prevent bony erosions and also exhibit low efficacy Their 
exact mechanism of action is not known, but, these drugs have been found to decrease 
monocyte IL-I , retard phagocyte chemotaxis  and also consequently inhibit B 
lymphocytes.  
Sulfasalazine
32 
 Sulfasalazine has anti-inflammatory activity and suppresses the disease 
condition in large number of Rheumatoid Arthritis patients. The exact mechanism of 
action is not known. Sulfapyridine split off in the colon through bacterial action and 
absorbed systemically seems to be the active moiety (but in ulcerative colitis 5-amino 
salicylic acid which acts locally in colon is the active component). It suppress the 
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generation of superoxide radicals and elaboration of cytokine by inflammatory cells. 
Sulfasalazine was reported to possess some side effects like Gastrointestinal intolerance 
, nausea, abdominal discomfort which occur in first 2 to 3 months of therapy and in later 
may be minimized by increasing the dose gradually  and is widely used as a second line 
drug. Cutaneous adverse events include urticarial, photosensitive eruption and pruritus. 
Leukopenia and neutropenia were also observed in 1-5% of patients. 
Leflunomide
31 
 This is an immunomodulation drug which inhibits proliferation of activated 
lymphocytes in rheumatoid arthritis patients. It suppress arthritic symptoms and 
radiological progression of disease. It also depress the production of antibody by B-
cells. Its efficacy has been found equal to methotrexate in clinical trial. It has been 
rapidly converted in the body to an active metabolite which acts by inhibiting dihydro-
orotate dehydrogenase and pyrimidine synthesis in actively dividing cells. Adverse 
effects of leflunomide are nausea, diarrhoea, headache, loss of hair, leucopenia, 
thrombocytopenia .It will not be used in children and pregnant/lactating women.  
Gold
32 
 Gold is one of the most effective agents in arresting the rheumatoid process. It 
diminishes phagocytosis, macrophage and lysosomal activity, phagocyte differentiation 
and also cell mediated immunity.  Erythrocyte sedimentation rate and rheumatoid factor 
level were lowered. It greatly bound to plasma and tissue protein and stays in the body 
for years. Gold is rarely used now because intake of parenteral gold salt may provoke 
hypotension, stomatitis, kidney and liver damage, bone marrow depression etc  
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C) Biologic response modifiers
31 
 These are recombinant proteins/monoclonal antibodies that bind and inhibit 
cytokines such as TNF  or IL-l .TNF  inhibitors mainly suppress macrophage and T-
cell function. It Provide quicker response than DMARDs though side effects are few, 
susceptibility to opportunistic infections like tuberculosis and pneumocystis pneumonia 
will be increased. Etanercept, adalimumab, infliximab are some of TNF  inhibitors. 
Anakinra is a IL-1 receptor antagonist and this drug was found to be clinically less 
effective than TNF   inhibitor26.  
D) Adjuvant drugs 
Corticosteroids  
 Corticosteroids are used because of their potent immunosuppressant and anti-
inflammatory activity. These drugs have been used only in more severe cases because 
of its serious disadvantages. Most of its side effects are found to be dose and duration 
dependent. Corticosteroids may cause aggravated hypertensaion, stimulation of cataract 
growth, glucose intolerance, difficulties in wound healing etc. 
OTHER MEASURES 
 Physiotherapy 
 Rest 
 Occupational therapy 
 Regular exercise33 
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3.2 PHARMACOLOGICAL INVESTIGATION 
3.2.1 Reviews related to anti-arthritic activity of Nimbadi plants 
 Dimple N. Thakkar et al (2016)., investigated anti-arthritic activity of Psoralea 
corylifolea and Clozapine in rats. They concluded that Psoralea corylifolea and 
Clozapine shows anti-arthritic effect in Complete Freund‘s adjuvant induced arthritis 
and the activity may probably due to the presence of Coumarins (Psoralidin) in 
Psoralea corylifolea seeds and because of the immunosuppressant effect of Clozapine. 
They also reported that combined treatment with Clozapine and Psoralea corylifolea 
produces Synergistic effect.
34 
 Ramya et al (2016)., evaluated the anti-arthritic activity of various extracts of 
Tinospora cordifolia by BSA denaturation method. The percentage of protein 
denaturation by different bark extracts of Tinospora cordifolia at concentration 100μg, 
250μg and 500μg were found to be 23%, 36%, 43% for methanol extract ,19%, 28%, 
37% for ethanol extract and 43%, 58%, 66% for chloroform extract respectively . From 
the study it had been concluded that chloroform extract and methanol extract exhibit 
potential capability to inhibit the denaturation of protein when compared with 
diclofenac sodium which was used as a standard drug.
35
. 
 Dev Prakash et al (2016)., evaluate anti-arthritic activity of alcoholic extract of 
rhizome of ginger (AERZO ) and  aqueous extract of rhizome of ginger (AQERZO) 
using formaldehyde induced arthritic rats. In formaldehyde treated group (disease 
control) 83.5% increase in edema volume was recorded on 1st day and was gradually 
increased to a maximum of 89.02% on 10th day. Whereas, standard drug indomethacin 
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had significantly reduced oedema volume on 1
st
 day it self (16.03%) and time 
dependent reduction in edema volume up to 10
th
 day. In standard group maximum 
percentage reduction in edema was recorded as 58.63%.  AERZO in different doses 
(100, 200 & 400 mg/kg ) exhibited time dependent significant reduction in edema 
volume. Likewise, AQERZO in different doses (100, 200 & 400 mg/kg ) also exhibited 
time dependent significant reduction in edema volume. From this study it was 
concluded that AERZO and AQERZO in 400mg/kg dose exhibited almost similar effect 
on percentage change in edema volume on 10
th
 day 58.11% & 57.59% respectively as 
compared to Indomethacin (10mg/kg) 58.63%. The preliminary phytochemical analysis 
of AERZO and AQERZO showed the presence of carbohydrates, sterols, flavonoids, 
glycosides, fixed oils, fats, saponins and alkaloids . As flavonoids has been reported to 
inhibit the cyclooxygenase enzyme thereby inhibiting prostaglandin synthesis which are 
responsible for development of arthritis, it may be responsible for the reported anti-
arthritic activity.
36 
 Rohit Kumar et al (2016)., investigated the anti-arthritic activity of Picrorhiza 
kurroa , on formaldehyde and adjuvant induced arthritis (AIA) in rat. They reported that 
administration of Picrorhiza kurroa rhizome extract (PKRE) significantly inhibited 
joint inflammation in both animal models. In adjuvant induced arthritic rat, treatment 
with PKRE shows considerable reduction in synovial expression of interleukin-1β, 
interleukin-6, tumor necrosis factor receptor-1 and vascular endothelial growth factor as 
compared with control. . Histopathology of paw tissue also displayed decreased 
inflammatory cell infiltration as compared with control. Finally these results 
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demonstrated the anti-arthritic activity of Picrorhiza kurroa against experimental 
arthritis.
37 
 Amar p. patil et al (2014)., evaluated the invitro anti-arthritic activity of Cassia 
tora linn. leaves by membrane stabilization and protein denaturation methods. Anti-
arthritic activity of both aqueous and ethanolic extract of Cassia tora linn. leaves were 
studied ,among these aqueous extract of Cassia tora linn. leaves showed significant 
activity.
38 
 A.F. Zahidah et al (2012)., studied the anti-arthritic activity of curcumin (major 
constituent present in the rhizomes of Curcuma longa ). In this study, collagen-induced 
arthritis (CIA) model was employed and Sprague-Dawley rats were used. Body weight, 
arthritic score and radiology scores were determined at specific intervals during the 
course of study. Results indicated that the mean radiology and arthritic scores for 
animals treated with Curcumin were significantly lower when compared with the 
negative control.
39
 
 Jong Bae Seo et al (2012)., evaluate the anti-arthritic and analgesic effect of 
standardized ethanol extract of Terminalia chebula . They induced Arthritis by using 
bovine type II collagen and treated the test group with standardized extract of 
Terminalia chebula  for 5 weeks. Results showed reduction in the arthritis index in a 
dose-dependent manner. There were also significant decrease in the number of T cell 
subpopulations in the lymph nodes and the serum levels of pro-inflammatory cytokines 
TNF-α, IL-6, and IL-1β in mice treated with extract of Terminalia chebula. The extract 
also reduced the number of abdominal contractions in acetic acid-induced writhing 
model in mice, which suggests analgesic effect of this extract.
40 
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 Uma Chandur et al (2011) ., studied the anti-arthritic activity of three different 
extracts (petroleum ether, chloroform, alcoholic ) of  Saussurea lappa .The anti-arthritic 
activity was evaluated  by using Complete Freund‘s Adjuvant (CFA) induced arthritis 
model. They formulated all the three extracts as a 3% ointment using poly ethylene 
glycol base. The animals were treated for 28 days. They measured the changes in the 
paw volume every day up to 28 days following CFA injection .The phytoconstituent 
analysis revealed the presence of alkaloids, carbohydrates, flavonoids, glycosides, 
phenol, saponins and tannins. Application of all the three extracts exhibited significant 
(p<0.01) edema inhibition when compared with the arthritic control group. Finally the 
results obtained suggest that Saussurea lappa root extracts were found to have anti-
arthritic activity.
41 
 Sandeep biradar et al (2010)., evaluated the anti‐inflammatory, anti‐arthritic, 
analgesic and anticonvulsant activity of Cyperus esculentus linn. and Cyperus rotundus 
Linn. essential oils. On phytochemical analysis oil shows presence of flavonoids, 
triterpenoids, carbohydrate, proteins. In this study they evaluate anti‐inflammatory 
activity using  carrageenan induced inflammation, anti-arthritic activity using 
formaldehyde induced arthritis model. The results showed dose dependent activity, 
indicated by reduction in paw edema in anti-inflammatory and antiarthritic activity, and 
significant reduction (p<0.01) in the MES induced convulsion in comparison to control. 
From the results obtained, it can be concluded that essential oil possess a good anti‐
inflammatory, anti‐arthritic, analgesic and anticonvulsant activities.42 
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 Vyas Amit S et al (2010)., evaluated anti-arthritic and vascular protective effects 
of Trigonella foenum-graecum (methi), Boswellia serrata and Acacia catechu alone and 
in Combinations. They induce arthritis using complete freund‘s adjuvant (0.1 ml) and 
measured various parameters like body weight, RA Factor, paw volume, E.S.R, WBC 
counts, arthritic index. Endothelial dysfunction and vascular studies were done by 
taking concentration response curve of peroxynitrite and acetylcholine respectively 
using Rat thoracic aorta strip which was pre-contracted with Phenylephrine. The results 
showed that Methi, Boswellia and Acacia individually, in dual and triple combinations 
possess potent anti-arthritic and vascular restoration activity (except Acacia alone).
43
  
3.2.2 Reviews related to Nimbadi churna 
 Parveen Kumar et al (2015)., treated a 62 year old man affected by Psoriasis 
with  Nimbadi Churna : 1.5 g ,Sudarshan Churna : 1g ,Kutaki Churna: 1g ,Giloye 
Churna: 1 g Three times a day with water. Within 2 weeks of treatment patient reported 
70 % relief in terms of symptoms like scaling and itching; and the patches vanished 
from most of the areas of the body we can provide subjective and objective relief to the 
Psoriasis patients.
44 
 K.YaminI et al (2010)., evaluated the anti-inflammatory activity of Nimbadi 
thailam against egg white induced inflammation on Swiss albino rats. They used 
Piroxicam gel as a standard drug and Nimbadi thailam was applied topically. The paw 
volume of animals treated with standard drug (piroxicam) and test formulation were 
compared with the paw volume of untreated control animals at constant intervals of 0, 
30, 60, 120 and 180 mins .The maximum activity was observed during 2nd and 3rd 
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hour. Finally the results show that topical application of Nimbadi thailam exhibited 
significant anti-inflammatory activity when compared with the Piroxicam gel and 
normal saline.
45
                     
3.2.3 Reviews related to anti-oxidant activity of Nimbadi plants 
 Neha Upadhyay et al (2014)., investigated anti-oxidant  activity by DPPH assay 
and total phenolic content of Tinospora cordifolia bark extract and their relation. Folin-
Ciocalteu reagent was used to determine total phenolic content. They observed a 
correlation between antioxidant activity and total phenolic content of the extracts. 
Results showed that the ethanolic bark extract exhibit the highest free radical 
scavenging activity (71.49%) whereas the free radical scavenging activity of methanolic 
extract was poor when compared to the ethanolic extract. Ethanolic bark extract also 
had the highest phenolic content of 84.62 ± 0.12 mg/g. These results showed that the 
antioxidant activity (r = 0.99) was positively correlated with the total phenolic content 
(r = 0.98) and also it suggested that ethanolic extract of Tinospora cordifolia had potent 
antioxidant activity and shall be explored as a novel natural antioxidant.
14 
  Barua cc et al (2014)., screened chloroform(PC), ethyl-acetate(PEA), 
ethanol(PE), hexane(PH), hydro-ethanol(PH) and aqueous (PA) extracts of seeds of 
Piper longum for invitro antioxidant activity by performing DPPH assay, ABTS assay, 
Nitric oxide radical scavenging activity, Hydroxyl radical scavenging activity and 
reductive ability assay. Ascorbic acid was used as reference standard. The extracts were 
also screened for anti-mycobacterial activities against Mycobacter smegmatis. The 
mean minimum inhibitory concentration (MIC) of different extracts PC, PH, PE, PEA 
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was found to be 8, 16, 16 and 32 mg/mL respectively. Finally they concluded that 
Chloroform extract of Piper longum (PC) showed the highest in vitro antioxidant 
activity as well as anti-mycobacterial activity. 
15 
 Karuna S. Verma et al (2014) ., evaluated anti-oxidant potential of young pods 
of Acacia catechu. They extracted the pods of Acacia catechu sequentially with 
solvents of decreasing polarity. Ascorbic acid was used as a standard. Ethyl acetate  
extract showed good antioxidant activity and was able to scavenge peroxide and DPPH 
free radicals.
16 
 K. Kant et al (2013)., investigated antioxidant study of Picrorhiza kurroa 
leaves. They isolated two pure compounds, luteolin-5-O-glucopyranoside and picein 
from butanol extract through column chromatography and also quantified different 
extracts (ethanol, ethyl acetate, butanol) of Picrorhiza kurroa leaves for isolated 
compound by high-performance liquid chromatography. They evaluated antioxidant 
activity of all the extracts using DPPH assay and ABTS scavenging assay. Butanol and 
ethyl acetate extract showed greater antioxidant activity when compared to ethanol 
extract. Luteolin-5-O-glucopyranoside and ascorbic acid showed nearly similar 
antioxidant activity whereas picein showed no activity at standard concentration.
17
  
 Mary Omwamba et al (2013)., evaluated the antioxidant activity of Hordeum 
vulgare L. by in vitro methods like Fe2+- Chelating activity assay , Hydroxyl radical 
scavenging assay , Superoxide radical scavenging assay and also by in vivo methods. 
Results showed that the extract exhibited high ability to chelate ferrous ions and 
scavenge hydroxyl and superoxide radicals. There exist a significant increase in the 
total antioxidant capability (T-AOC) and increased level of antioxidant enzymes 
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superoxide dismutase (SOD) and glutathione peroxidase, while levels of malondia- 
lodehyde (MDA) and manoamine oxidase (MAO) decreased in both the liver and brain 
of aged mice treated with the extract compared to the control (untreated mice). The 
results demonstrated potential antioxidant, antiaging effect of Hordeum vulgare L.
18 
 Oyas Ahmed Asimi et al (2013)., evaluated antioxidant and antimicrobial 
activity of ethyl acetate extracts of five Indian spices viz., Curcuma 
longa,Cinnamomum zeylanicum,Cuminum cyminum,Zingiber officinale and Allium 
vineale . They evaluated the  anti-oxidant ativity by DPPH method,FRAP method and 
TPC assay. The antioxidant capacity of the spice extracts were found in descending 
order: Cumin>Garlic>Cinnamon>Turmeric>Ginger by DPPH method, Garlic> Cumin> 
Turmeric>Ginger>Cinnamon by FRAP method and 
Turmeric>Cinnamon>Garlic>Cumin>Ginger by TPC method. Cinnamon extract 
showed highest antimicrobial effect (12mm) at maximum concentration on the growth 
of bacterial strains Vibrio vulnificus and Micrococcus luteus followed by cumin (9mm), 
Garlic (8mm), Ginger (8mm) and Turmeric (7mm).
14
  
 Gupta priya et al (2012)., evaluated the anti-oxidant and anti-microbial activity 
of  methanolic extract of Emblica  officinalis seeds. Anti- microbial activity was 
evaluated by Agar well diffusion method and free radical scavenging activity of seed 
extract by DPPH assay, Hydrogen  peroxide method and Reducing power ability assay. 
Results showed maximum relative percentage inhibition against S.aureus(91.11%) and 
lowest percentage inhibition against Enterococcus (59.17%). IC50 value of  Emblica  
officinalis ethanolic extract was found to be 15µg/ml by DPPH assay and 32µg/ml by 
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Hydrogen  peroxide method respectively. Whereas IC50 value of ascorbic acid was 
found to be 12 µg/ml by both DPPH assay and Hydrogen  peroxide method .
15 
 Sirappuselvi S.et al (2012)., evaluated invitro antioxidant activity of methanolic 
extract of Cassia tora leaves. They found that extract of cassia tora leaves reduce DPPH 
radicals in concentration dependent manner with an IC50 value of (35.59 μg/ml) and 
exhibit IC50 value of (49.36 μg/ml) in inhibiting nitric oxide radical. Cassia tora also 
showed hydrogen peroxide scavenging activity in a concentration dependent manner 
with an IC50 value of 40.49 μg/ml. From the results obtained they had concluded that 
Cassia tora exhibit  potent invitro antioxidant activity.
16 
 Kyung-Mi Chang et al (2012)., investigated the anti-oxidant activity of 
Saussurea lappa C.B. Clarke. They extracted roots with ethanol at room temperature 
and then the extract were fractionated successively with hexane, chloroform, and n-
butanol. Total phenolic and flavonoid content present in the extracts were determined 
by the Folin-Ciocalteu‘s colorimetric and aluminum nitrate method, respectively. They 
found that total phenolic and flavonoid contents of n-butanol soluble fraction were 
higher than when compared with other solvent fractions. and the ethanol extract. They 
also found that the n-butanol soluble fractionates of Saussurea lappa C.B. Clarke 
showed the strongest inhibitory potential on 2,2-diphenyl-1-picrylhydrazyl (DPPH) 
radical.
17 
 A. Elayaraja et al (2010)., investigated antioxidant potential of ethanolic and 
hydro alcoholic extracts of roots and rhizomes of Acorus calamus Linn by DPPH assay 
and compared the results with butylated hydroxyl anisole (BHA) and silymarin. 
Percentage inhibition of free radical by ethanolic and hydro alcoholic extracts was 
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found to be 59.13  18.95 and 56.71 19.54 respectively. It was concluded that of 
ethanolic extract showed the maximum antioxidant activity.
18 
 B. Kiran et al (2010)., evaluated the antioxidant properties of extract of 
Psoralea corylifolia L. seeds by employing different standard assays. Results shown 
that all the extracts tested were effective in quenching superoxide anion and maximum 
superoxide scavenging activity was detected in the alcohol and water (1:1) extract ( 
200μg/ml). Lipid peroxidation was evaluated by production of thiobarbituric acid 
reactive substances (TBARS) in RBC membrane and highest antioxidant activity (71.0 
%) was observed in the alcohol water extract at concentration of 50μg/ml. Maximum 
hydroxyl radical scavenging activity of 87.0 % was observed at concentration of 
20μg/ml. Similarly maximum 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical 
scavenging activity of 89.0 % was observed at 25μg/ml in alcohol water extract when 
compared with standard tocopherol and Butylated hydroxy anisole. Finally results 
suggested that alcohol and water (1:1) extract of seeds of P. corylifolia exhibit strong 
antioxidant potential.
24 
3.2.4 Reviews related to standardisation of churna 
 Standardization of Ayurvedic preparations enables us to recognise the quality of 
the formulation. The Central Council of Research in Ayurveda and Siddha has 
prescribed the preliminary guidelines for testing the quality of various ayurvedic 
formulations.
29 
 Fathima grace Xavier et al (2014)., standardized Surya Sakthi Churna a poly 
herbal churna available in the market. They procured and standardized the churna for 
the parameters like organoleptic characters, physical characters, physiochemical 
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properties and phytochemical screening etc. These parameters can determine the quality 
of the product. The results were found to be within the standards.
46 
 J Karthi et al (2012)., standardised sudharshana churna on the basis of its 
organoleptic characters, physical characteristics, physico-chemical properties and 
Preliminary phytochemical analysis. They determine water soluble and choloroform 
soluble extractive. The ash values of the samples were determined based on the method 
as described by the World Health Organisation (WHO) guidelines for medicinal plant 
materials. The results obtained with the marketed formulations and the in-house 
formulations were compared and variation was found to be insignificant.
47 
 
3.2.5 Reviews related to arthritis induction 
There are certain models available to induce arthritis in laboratory animals. They are, 
 Complete Freund‘s adjuvant induced model34,37,41,43 
 Collagen-induced model39,40 
 Formaldehyde-Induced model42 
 Complete Freund‘s adjuvant induced model is the most frequently investigated 
model of chronic inflammation and it depicts very close similarity with the human 
rheumatoid arthritis. It has been used for the evaluation of anti-arthritic activity of 
various plant extracts like Psoralea Corylifolea
34
, Picrorrhiza kurroa
37
, catechu
43
.
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3.3 DRUG PROFILE 
  In Ayurveda the term Churna refers to a fine powder of a drug or drugs 
which is prepared by mixing clean, finely powdered and sieved drugs.
48
 Nimbadi 
churna is a classical Ayurvedic formulation which consist of about 21 ingredients. It 
was mentioned in ―The Ayurvedic Formulary of India‖ for the treatement of 
diseases of abdomen, diseases of skin, Rheumatism, Gout.
25 
3.3.1 List of ingredients of Nimbadi churna
25 
S.no Sanskrit Name Botanical Name Part 
 
Quantity 
 
 
1. 
 
Nimba Azadirachta indica A.Juss. Stem bark 48g 
 
2. 
 
Amrita Tinospora cordifolia Willd.Miers Stem 48g 
 
3. 
 
Abhaya Terminalia chebula Retz. Pericarp 48g 
 
4. 
 
Dhatri Emblica officinalis Gaertn. Pericarp 48g 
 
5. 
 
Somaraji Psoralea corylifolia Linn. Seed 48g 
 
6. 
 
Sunthi Zingier officnale Rosc. Rhizome 12 g 
 
7. 
 
Vidanga Embelia ribes Burn.f Fruit 12 g 
 
8. 
 
Edagaja Cassia tora Linn. Seed 12 g 
 
9. 
 
Kana Piper longum Linn. Fruit 12 g 
10. 
 
Yavani Tracyspermum ammi Sprauge. Fruit 12 g 
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11. 
 
Ugragandha Acorus calamus Linn. Rhizome 12 g 
 
12. 
 
Jeeraka Cuminum cyminum Linn,. Fruit 12 g 
 
13. 
 
Katuka Picrorrhiza kurroa oyle.ex Benth Rhizome 12 g 
 
14. 
 
Khadira Acacia catechu Linn. Heartwood 12 g 
 
15. 
 
Saindhava Rock salt - 12 g 
 
16. 
 
Yavakshara Hordeum vulgare Linn. Water soluble ash 12 g 
 
17. 
 
Haridra Curcuma longa Linn. Rhizome 12 g 
 
18. 
 
Daru haridra Berberis aristata DC. Stem 12 g 
 
19. 
 
Musta Cyperus rotundus Linn, Rhizome 12 g 
 
20. 
 
Devadaru Cedrus deodara Roxb Heartwood 12 g 
 
21. 
 
Kushta Saussurea lappa C.B.Clarke Root 12 g 
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3.3.2 Pharmacological actions of ingredients of Nimbadi churna 
S.no Botanical Name 
 
Pharmacological actions 
 
 
1. 
 
Azadirachta indica 
A.Juss. 
Anti-microbial, Anti-inflammatory, ,Hepatoprotective , 
Anti-diabetic , Immunomodulation, Anti cancer, Anti-
oxidant, wound healing, Neuro protective.
49 
 
2. 
 
Tinospora cordifolia 
Willd.Miers 
Anti-inflammatory ,Hepatoprotective , Anti-diabetic 
,Treating Skin diseases, Immunomodulation, anti-
neoplasic, Anti-pyretic.
50-51 
 
3. 
 
Terminalia chebula 
Retz. 
Anti-bacterial, Anti-viral, Anti-arthritic 
,Hepatoprotective , Anti-diabetic , Immunomodulation, 
Anti-neoplasic, Anti-pyretic, Anti-oxidant, Wound 
healing.
52 
 
4. 
 
Emblica officinalis 
Gaertn. 
Anti-cancer, Anti-ulcer, Cardioprotective,Anti oxidant, 
Immunomodulatory, Anti-pyretic, Analgesic, 
Hepatoprotective, Anti-tussive, Gastroprotective, 
Memory enhancer
53
. 
 
5. 
 
Psoralea corylifolia 
Linn. 
Laxative, Anti-bacterial, Anti-inflammatory 
,Hepatoprotective , Anti-neoplasic, Anti-oxidant, 
Wound healing, Diuretic.
54 
 
6. 
 
Zingier officnale 
Rosc. 
Anti-tussive, Anti-emetic, Anti-inflammatory, Anti-
bacterial, Anti-arthritic, Immunomodulatory effect, 
Anti-neoplasic, Anti-oxidant.
55 
 
7. 
 
Embelia ribes Burn.f 
Antibiotic,, Antifungal ,Antifertility, Diuretic, 
laxative.
56,57 
 
8. 
 
Cassia tora Linn. 
Anti-fungal, Anti-inflammatory, ,Hepatoprotective , 
Anti-nociceptive , Anti cancer, Antioxidant, 
Anthelmintic, Hypolipidemic, Hypotensive.
58 
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9. 
 
Piper longum Linn. 
Hepatoprotective ,Anti-bacterial, Anti-inflammatory , 
Hepatoprotective , Immunomodulation, Anti-asthmatic, 
CNS stimulant.
59 
 
10. 
 
Tracyspermum ammi 
Sprauge. 
Anti-microbial, Anti-hypertensive , Hepatoprotective, 
Immunomodulation, Anti-inflammatory, 
Hypolipidaemic, Diuretic, Anti-inflammatory, Anti-
tussive.
60 
 
11. 
 
Acorus calamus Linn. 
Anti-microbial ,Hepatoprotective , Anti-diabetic, Anti-
neoplasic, Anti-inflammatory, Anti-oxidant, Anti-ulcer, 
Anti-convulsant, Anti-anxiety.
61,62 
 
12. 
 
Cuminum cyminum 
Linn,. 
Anti-microbial, Anti-inflammatory , Anti-diabetic , 
Immunomodulation, Anti-cancer ,Anti-oxidant, 
Hypolipidemic, Anti-oesteoporotic, Hypotensive.
63 
 
13. 
 
Picrorrhiza kurroa 
oyle.ex Benth 
Anti-cancer, Anti-arthritic, Cardioprotective, Anti-
oxidant, Nephroprotective.
64 
 
14. 
 
Acacia catechu Linn. 
Anti-inflammatory, Anti-microbial, Hepatoprotective , 
Anti-diabetic , Anti-cancer, Anti-oxidant, wound 
healing, Anti-pyretic.
65 
 
15. 
 
Rock salt 
Digestive disorders , Respiratory disorder, Rheumatoid 
arthritis, Anti-obesity.
66 
 
16. 
 
Hordeum vulgare 
Linn. 
Laxative, Diuretic, Anti-hypercholesterolemic.
67 
 
17. 
 
Curcuma longa Linn. 
Anti-inflammatory ,Hepatoprotective , Anti-diabetic , 
Anti-cancer, Anti-microbial, Anti-oxidant, Anti-
asthmatic, Alzheimer‘s disease.68 
 
18. 
 
Berberis aristata DC. 
Anti-microbial, Anti-inflammatory , Anti-diabetic , 
Immunomodulation, Anti-cancer, Anti-oxidant, Anti-
malarial.
69 
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19. 
 
Cyperus rotundus 
Linn, 
Anti-diarrheal, Anti-allergic, Anti-ulcer, Cardio 
protective , Anti-diabetic, Anti-inflammatory, Anti-
oxidant, Wound healing.
70,71,72 
 
20. 
 
Cedrus deodara 
Roxb 
Anti-tubercular, Anti-convulsant, Anti-arthritic , Anti-
ulcer , Immunomodulator,  Anti-oxidant, Wound 
healing, Anti-inflammatory, Diuretic.
73 
 
21. 
 
Saussurea lappa 
C.B.Clarke 
Anti-spasmodic, Anti-inflammatory, Anti-ulcer , 
Hepatoprotective , Anti-diabetic , Immunomodulator.
74 
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5. MATERIALS AND METHODS 
5.1 PROCUREMENT AND EXTRACTION OF NIMBADI CHURNA 
 Nimbadi churna was procured from Vyas pharmaceuticals, India and about 
100g of churna was macerated by cold maceration with 50% methanol for 72 h , 
with occasional shaking. Macerate was decanted and filtered, concentrated and kept 
in a vacuum desiccator for complete removal of solvent. The percentage yield was 
calculated and it was packed in air tight container.
75,76 
5.2 STANDARDISATION OF NIMBADI CHURNA 
 Standardization of herbal formulation is necessary in order to assess the 
quality of drugs.
77
 Nimbadi churna was standardized for the parameters like 
organoleptic characters, physical characters, physiochemical properties etc., to 
determine the quality of the product. 
5.2.1 ORGANOLEPTIC EVALUATION
25 
 The colour, odour and taste of the formulation were evaluated manually. 
5.2.2 PHYSIOCHEMICAL EVALUATION
25 
A) Determination of Total Ash 
 To determine total ash about 2 to 3 g of churna was incinerated at a 
temperature not exceeding 450°C  in a tarred silica crucible until free from carbon 
then cool and weigh. Then the percentage of total ash was calculated. 
B) Determination of Acid-Insoluble Ash 
 To determine acid-insoluble ash the residue of ash obtained in total ash was 
added with 25ml of dilute hydrochloric acid and boiled for 5mins.Then this was 
filtered using ashless filter paper and ignited again to determine the acid insoluble 
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ash. The content of acid-insoluble ash was calculated with reference to the air-dried 
drug. 
C) Determination of Alcohol Soluble Extractive 
 5g of churna was macerated with 100ml of alcohol in a closed flask for 
twenty-four hours (shaking frequently during first six hours and allowing to stand 
for eighteen hours).It was then filtered and the filtrate was evaporated until constant 
weight was obtained. The percentage of alcohol-soluble extractive was calculated 
with reference to the air-dried drug. 
 
D) Determination of Moisture Content (Loss on Drying) 
 10g of the churna was accurately weighed and transferred into a tared 
evaporating dish. This was dried at 105°C for 5hrs with regular check of weight for 
every interval. Drying was continued until difference between two successive 
weighing corresponds to not more than 0.25 percent. Constant weight is reached 
when two consecutive weighing after drying for 30 minutes and cooling for 30 
minutes in a desiccator, showed not more than 0.01 g difference. 
E) Determination of pH Value 
 PH value of the churna was determined using pH meter by dispersing 10% 
w/v churna in water. 
5.2.3 PHYSICAL CHARACTERS
46 
A) Bulk density and tapped density 
 Bulk density refers to a measure used to describe a packing of particles or 
granules. It was determined by taking 10g of churna in a graduated measuring 
cylinder and tapped on a wooden surface. The initial volume and the tapped volume 
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was noted. From the initial volume  bulk density was calculated and from the tapped 
volume tapped density was calculated using the formula. 
 
Bulk density =    
            
           
 
 
Tapped density =    
            
             
 
B) Angle of Repose 
 Angle of Repose has been used as an indirect method of quantifying powder 
flow ability because of its relationship with interparticle cohesion. It was determined 
by using funnel method. The powder was allowed to flow through a funnel fixed on 
a stand to form a heap and the angle of repose was calculated using the formula. 
Angle of repose, θ =      
 
 
 
Where, 
h = Height of heap 
r =Radius of heap 
C) Hausner’s Ratio 
             Hausner’s ratio is related to inter particle friction and as such can be used to 
predict the powder flow properties. It can be calculated using formula 
Hausner’s Ratio =  
             
            
 
D) Compressibility/Carr’s Index 
 Carr‘s index is an indirect method of measuring the powder flow from bulk 
density.It was calculated using the formula 
Carr’s Index =  
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5.3 PHYTOCHEMICAL SCREENING
 
5.3.1 Detection of alkaloids
78 
Mayer’s test : About 50mg 0f extract was stirred with 2 ml of dilute 
hydrocholoric acid and filtered. To a 2 mL of filtrate, one or two drops of Mayer‘s 
reagent was added along the sides of the test tube. A white creamy precipitate 
indicated the test as positive. 
5.3.2 Detection of phenolic compound
79 
 Ferric chloride test: The extract (50 mg) was dissolved in 5mL of distilled 
water. To this, few drops of neutral 5% ferric chloride solution were added. A dark 
green color indicated the presence of Phenol. 
5.3.3 Detection of glycosides
78 
 Borntrager’s test: 50 mg of extract was hydrolysed with 5mL of 
concentrated hydrochloric acid for 2h on a water bath,then filtered and the 
hydrolysate was subjected to the following tests.To 2 mL of filtrate hydrolysate, 
3mL of chloroform was added and shaken, choloroform layer was separated and 
10% ammonia solution was added to it. Pink colour indicated the presence of 
glycosides 
5.3.4 Detection of terpenoids
78 
Libermann-Burchard test: 0.5 g of the extract was added in 2 ml of chloroform. 
Concentrated H2S04 (3ml) was carefully added to form a layer. A reddish brown 
coloration of the interface indicates the presence of terpenoids. 
MATERIALS AND METHODS            
 
 
 
Institute of Pharmacology,MMC 34 
 
5.3.5 Detection of flavonoids
78 
 0.5g of extract was dissolved in 5mL of Distilled water and filtered. 1mL of 
the extract filtrate was heated with 10 ml of ethyl acetate over a steam bath for 3 
min. The mixture was filtered and 4 ml of the filtrate was shaken with 1 ml of dilute 
ammonia solution. A yellow coloration indicates the presence of flavonoids. 
5.3.6 Detection of tannins
79 
About 0.5 g of the extract was boiled in 10 ml of water in a test tube and then 
filtered. A few drops of 0.1% ferric chloride was added and observed for brownish 
green or a blue-black coloration 
5.3.7 Detection of reducing sugars 
Fehling’s test: About 100mg of extract was dissolved in 5mL of water and 
filtered. The filtrate was subjected to the following test. Then 1 mL of filtrate was 
boiled on water bath with 1ml each of fehling‘s solution I and II. A red precipitate 
indicated the presence of reducing sugar. 
5.3.8 Detection of saponins
78 
 Foam test: The extract (50 mg) was diluted with 5mL distilled water. The 
suspension was shaken in a graduated cyclinder for 15 min. A 2cm layer of foam 
indicated the presence of saponins. 
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5.4 INVITRO ANTIOXIANT ACTIVITY 
5.4.1 DPPH RADICAL SCAVENGING ASSAY
81 
Principle 
 DPPH (1, 1-diphenyl-2-picrylhydrazyl) is a stable free radical and 
delocalization of its electron gives rise to the deep violet color, characterized by an 
absorption band in ethanol solution centered at about 517 nm. When a solution of 
DPPH is mixed with a substrate that can donate a hydrogen atom, then this gives rise 
to the reduced form with the loss of this violet color. So normally to evaluate the 
antioxidant potential of the test samples, a solution of DPPH has been mixed with a 
test sample and the change in optical density of DPPH radicals will be monitored.  
 
Procedure 
 The free radical-scavenging activity of Nimbadi churna was measured by 
DPPH radical scavenging assay. For this, 1ml of DPPH solution (0.1mM) in 
methanol was added to different concentrations of churna. Thirty minutes later, the 
absorbance was measured at 517nm using a UV-Visible spectrophotometer . A 
control was prepared without adding churna. Rutin at various concentrations were 
used as a standard. The percent DPPH-scavenging activity was calculated using 
formula, 
DPPH Scavenged (%) = 
             
       
     
Where, 
Acontrol is the absorbance of control  
Atest is the absorbance of test 
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 The antioxidant activity of Nimbadi churna was expressed as IC50 and 
compared with the standard. 
5.5 INVIVO STUDIES 
5.5.1 MAINTENANCE OF ANIMALS
82 
 Wistar albino rats of uniform weight (150 -200g) without prior drug 
treatment were used for the study .Animals were obtained from Animal 
Experimental laboratory, Madras Medical College, Chennai -03. Animals were 
maintained on normal diet and purified water .They were housed in spacious 
polypropylene cages and paddy husk were used as bedding material. The animals 
were kept under standard conditions at 23-25°c, 12 hour light/dark cycle. 
 The animals were acclimatized to the laboratory conditions for a week prior 
to the experimentation. The handling of animals was made under the supervision of 
Animal ethics committee of this institution and principles of animal handling were 
strictly adhered. The experimental protocol was approved by Institutional Animal 
ethics committee (IAEC), Madras Medical College, Chennai -03., which was 
certified by the committee for the purpose of Control and Supervision of 
Experiments on Animals. 
Approval No: IAEC/MMC/03/2016                                        
  
5.5.2 ACUTE TOXICITY STUDY OF NIMBADI CHURNA
83 
 Acute oral toxicity study were carried out according to OECD guidelines – 
423 (OECD, 2001). Animals were fasted overnight prior to drug administration and 
food was withheld for a further 3-4 hours after administration of drug substance. A 
limit test at one dose level of 2000 mg/kg body weight was carried out with six 
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(three animals per step) female Wistar albino rats (as females are generally slightly 
more sensitive). 
 Animals were then observed individually after dosing atleast once during the 
first 30 minutes, periodically during the first 24 hours, with special attention given 
during the first 4 hours, and daily thereafter, for a total of 14 days. The animals were 
observed for changes in skin, fur, eyes, mucous membranes, respiration, and central 
nervous system. Individual weights of animals were determined shortly before 
administration of test substance and weekly thereafter and the changes in animal 
weight were recorded. 
 Test procedure with a starting dose of 2000 mg/kg body weight are given in 
fig: 3 
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Fig 3 : Test procedure with a starting dose of 2000 mg/kg body weight 
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5.5.3 ANTI-ARTHRITIC ACTIVITY 
A) Complete Freund's adjuvant induced arthritis
84 
 Male wistar albino rats with an initial body weight of 150 to 200 g were 
used. Arthritis was induced by single injection of 0.1 ml complete Freund‘s adjuvant  
(Sigma Aldrich) 
36 
into the sub plantar region of the left hind paw on 1st day. 
Freund‘s adjuvant  consists of mycobacterium tuberculosis being suspended in 
heavy paraffin oil. Injection of complete Freund‘s adjuvant into the rat paw induces 
inflammation as primary lesion within 3 to 5 days and secondary lesions occur 
approximately after 11 to 12 days which are characterized by inflammation of non-
injected sites (hind limb , forepaws, ears, nose and tail). 
 Methotrexate (1mg/kg) was used as a standard drug.
34
 It is a dihydrofolate 
reductase inhibitor with immunosuppressant and anti-inflammatory action. Dosing 
with the test compounds or the standard is started on the same day and continued for 
12 days. Nimbadi churna & Methotrexate were administered by oral gavage using 
oral feeding tube fixed to a syringe to administer the required quantity of drug. The 
treatment given to different groups of animal was given in table 3. 
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Table 3:  Grouping of animal 
 
 
 
GROUP 
NAME OF 
THE 
GROUP 
TREATMENT 
NO OF 
ANIMALS 
Group I 
Vehicle 
control 
0.5% CMC was given to rat from 1
st
 to 
12
th
 day 
6 
Group II 
Disease 
control 
Single dose of Complete Freund‘s 
adjuvant (0.1ml) on 1st day 
6 
Group 
III 
Standard 
group 
Single dose of Complete Freund‘s 
adjuvant (0.1ml) on 1st day and 
Methotrexate (1mg/kg body weight) were 
given to rats p.o for 12days 
6 
Group 
IV 
 
Low dose 
test group 
 
Single dose of Complete Freund‘s 
adjuvant (0.1ml) on 1st day and Nimbadi 
churna (250mg/kg) were administered p.o 
to rats for 
12 days (from 1st day to 12th day) 
6 
Group V 
 
High dose 
test group 
 
Single dose of Complete Freund‘s 
adjuvant (0.1ml) on 1st day and Nimbadi 
churna (500mg/kg) were administered p.o 
to rats for 
12 days (from 1st day to 12th day) 
6 
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b) Measurement of various parameters 
(i) Measurement of body weight
34 
 The body weight of all the animals were examined on 1
st
 day prior to 
Freund‘s adjuvant injection and consequently on , 7th, 14th, 21st days. 
(ii) Paw volume
34 
 Hind paw volume was measured by using plethysmometer (An instrument 
used to measure changes in paw volume).To measure paw volume immerse the limb 
of the animal and volume of mercury displacement was noted. Paw volume were 
immediately observed before arthritis induction (basal value) and then consequently 
on 7
th
, 14
th
 and 21
st
 days thereafter. 
(iii) Measurement of Arthritic index
84
  
 Arthritic index was scored on 13
th
 and 21
st
 day for all the animals. The 
animals were closely observed and scored as described in table 
Table 4:  Scoring of Arthritic index 
 
 
ORGANS INDICATION SCORING 
 
EARS 
Absence of nodules 0 
Presence of nodules 1 
 
NOSE 
No swelling of connective tissue 0 
Intensive swelling of connective tissue 1 
 
TAIL 
Absence of nodules 0 
Presence of nodules 1 
 
FORE PAW 
Absence of inflammation 0 
Inflammation of at least one joint 1 
 
 
 
HIND PAW 
Absence of inflammation 0 
Slight inflammation 1 
Moderate inflammation 2 
Marked inflammation 3 
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(iv) Hematological parameter
34 
Blood sample collection 
 At 21st day rats were anaesthetized using thiopentone sodium, and blood 
samples were collected from retro orbital junction (1 ml into sterile blood collecting 
tube for determination of Rheumatoid factor and 1 ml into EDTA-treated sterile 
blood collection tubes for measurements of RBC, WBC and HB ) from all the 
groups of animals. 
Hematological analysis 
 A sample of blood was taken from animal of all the groups and mix well in 
the EDTA contain test tube. The mixing of blood was done by rotating the sample 
gently between the palms of hands. This blood was used to determine Red Blood 
Cells (RBC), White Blood Cells (WBC) and hemoglobin. 
(v) SEROLOGICAL ANALYSIS 
RA Factor
34 
 Serum RA factor estimation was done using Latex turbidometry method 
using Latex flied test kit. 
Principle:  
 Serum rheumatoid factor is measured using turbidometry method of analysis. 
Turbidimetry is the measurement of the reduction in light transmission caused by 
particle formation. Light transmitted in forward direction is detected. The amount of 
light absorbed by suspension of particles depends on specimen concentration and on 
the particle size. Transmitted light was measured using visible spectrophotometer. 
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Reagents used 
Diluents (R1) - Tris buffer 20 mmol/L, having pH 8.2 Sodium azide 0.95 g/L  
Latex (R2) - Latex particles coated with human gamma globulin, having pH 7.4 
Sodium azide 0.95 g/L  
RF-CAL - Calibrator. Human serum. The RF concentration was stated on the Vial 
label. 
Preparations:  
 For RF calibrator: RF calibrator was reconstituted with 2.0 ml of distilled 
water. It was mixed gently and brought to room temperature for 10 minutes before 
use.  
For calibration curve (range from 20 to 160 IU/ml):  
 The following RF calibrator dilutions were prepared in the normal saline. 
The concentration of the RF calibrator was multiplied by the corresponding factor as 
stated in below table to obtain the RF concentration of each dilution. 
Table 5:  RF Calibrator Dilutions 
Calibrator 
dilution  
1  2  3  4  5  6  
Calibrator 
RF(μL)  
-  10  25  50  75  100  
                                             100 90  50  25  -  
Factor  0  0.1  0.25  0.5  0.75  1.0 
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For one point calibration (linear up to 100 IU/ml) 
 Preparation of RF calibrator dilution: 30 μL RF calibrator + 70 μL normal 
saline. The RF calibrator concentration was multiplied by 0.33 to obtain the RF 
concentration of the diluted calibrator. 
Procedure 
 The reagent and photometer (cuvette holder) were brought to 37°C. The 
instrument was adjusted to zero with distilled water. (Blank) .Then the reagents were 
pipette out into a cuvette and mixed. Then the absorbance was read after 2 minutes 
(A2) of the sample addition.  
Table 6:  Reagents 
Reagents A blank A2 Calibrator/ 
sample 
NaCl 9.0 g/l (μL) 7.0 - 
Calibrator or 
sample (μL) 
- 7.0 
R1: diluents (ml) 0.9 0.9 
R2: latex (ml) 0.1 0.1 
 
Calculations  
 For calibration curve: Absorbance difference (A2 - Ablank) of each point of 
the calibration curve was calculated and plotted on Y-axis against the RF 
concentration of each calibrator dilution on X-axis. RF concentration in the sample 
was calculated by interpolation of its (A2-Ablank) in the calibration curve.  
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For one point calibration:  
RF value = (A2sample-Ablank) / (A2calibrator-Ablank) X Diluted calibrator 
concentration 
 
(vi) Histopathology
37 
 On day 21, animals were sacrificed while they were under anaesthesia, and 
the paws and knees were removed and fixed for biological examination The entire 
paw tissue sections was fixed by immersion at room temperature in 10% neutral 
buffered formalin solution. The limbs were decalcified in EDTA and then processed 
for paraffin embedding, sectioned, and stained with hematoxylin–eosin. Then the 
sections were examined for arthritic changes. 
5.5 STATISTICAL ANALYSIS
36 
 The values are expressed as Mean ± Standard Error of Mean (SEM). P<0.05 
was considered statistically significant. Data obtained was analyzed by one-way 
ANOVA followed by Dunnett‘s multiple comparison using Graphpad prism version 
7. 
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6. RESULTS 
 This chapter includes various results obtained from the investigations 
performed throughout the study 
6.1 STANDARDIZATION OF NIMBADI CHURNA 
6.1.1 Organoleptic analysis of Nimbadi churna 
 Organoleptic analysis of Nimbadi churna was carried out and the results are 
depicted in Table 7 . 
Table 7: Organoleptic analysis of Nimbadi churna 
 
6.1.2 Physico-chemical parameters 
 Results obtained from the evaluation of various Physico-chemical parameters 
like Loss on drying ,Ash value, Acid-insoluble ash, Alcohol-soluble extractive, PH 
indicates was found to be within limits and the values are depicted in Table 8. 
 
 
 
S.No Parameters Observation 
Ayurvedic 
pharmacopial 
Standard 
1. Colour Yellowish brown Yellowish brown 
2. Odour Pungent Pungent 
3. Texture smooth smooth 
4. Taste Bitter and salty Bitter and salty 
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Table 8: Physico-chemical parameters of Nimbadi churna 
Values are expressed in Mean  S.E.M 
6.1.3 Physical evaluation of Nimbadi churna 
 Results obtained from physical evaluation of Nimbadi churna are depicted in 
the Table 9                                 
                                              Table 9: Physical evaluation 
S.No Parameters Observation 
1. Bulk densiy(g/ml) 0.311       
2. Tapped density(g/ml) 0.38       
3. Angle of repose(  ) 27°61‘ 0.65 
4. Compressibility index(%) 18.39 1.48 
5. Hausner‘s ratio 1.23      
                      Values are expressed in Mean  S.E.M 
 The practical yield of Nimbadi churna on maceration using methanol as a 
solvent was found to be 29.2% w/w. 
S.No Parameters Observation 
Ayurvedic 
pharmacopial 
limits 
Inference 
1. Loss on drying (%) 5±0.12 NMT 8% within limit 
2. Total ash value (% w/w) 11.46 0.27 NMT 12% within limit 
3. Acid-insoluble ash (% w/w) 9.46 0.27 NMT 10% within limit 
4. 
Alcohol-soluble extractive 
(% w/w) 
23.47      NLT 18% within limit 
6. PH 10%  aqueous solution 4.16      4-5 within limit 
RESULTS 
 
 
 
Institute of Pharmacology,MMC 48 
 
6.2 PHYTOCHEMICAL SCREENING  
 Nimbadi churna was subjected to various chemical tests for detection of 
phyto constituents and the results obtained are are illustrated in Table 10  and Fig 4. 
Table 10 : Phytochemical screening of Nimbadi churna 
S.no Chemical constituent Nimbadi churna 
1.  Alkaloids + 
2.  Flavonoids + 
3.  Reducing sugar + 
4.  Glycosides + 
5.  Phenolic compounds + 
6.  Tannins + 
7.  Saponins + 
8.  Proteins and amino acids + 
9.  Terpenoids + 
NOTE:    (+) Present                (-) Absent 
Fig 4: Phytochemical screening of Nimbadi churna 
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 Results obtained from phytochemical screening indicates the presence of 
alkaloids,flavonoids,reducing sugar,Glycoside,phenolic compound, tannins, 
saponin,Protein and amino acids ,terpenoids. 
6.3 IN VITRO ANTI-OXIDANT ACTIVITY  
 In vitro antioxidant activity of Nimbadi churna extract was evaluated by 
DPPH assay.The results obtained are are illustrated in Table 11 and fig 5. 
Table 11 : In vitro anti-oxidant activity 
S. No 
Conc. in 
µg/ml 
% inhibition 
 
Nimbadi 
churna extract 
Standard 
(Rutin) 
1 200 16.87 0.12 20.83 ± 0.318 
2 400 39.27      41.17 ± 0.549 
3 600 55.43      57.53 ± 0.338 
4 800 55.63      63.27 ± 0.348 
5 1000 67.76      70.68       
IC50 (µg/ml) 565.4 515.5 
Values are expressed in Mean ± SEM of triplicate determinations 
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Fig 5: Effect of Nimbadi churna on DPPH radical inhibition 
 
6.4 ACUTE ORAL TOXICITY STUDIES  
 Acute  toxicity study of Nimbadi churna was performed according to OECD 
guidelines 423. Results showed that ,at 2000 mg/kg dose nimbadi churna did not 
cause death of any animal and also there were no noticeable changes in the general 
behavior as well as no changes in water and food intake in treated animals. 
Therefore, Nimbadi churna comes under the category of Class 5 or unclassified and 
the LD50 was considered to be >2000 mg/kg. The testing doses were selected as 250 
mg/kg body weight and 500 mg/kg of body weight respectively. Behavioral changes 
and mortality rate of animal are given in table 12. 
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Table 12: Behavioral changes in animal during acute toxicity studies 
S.no Parameters Observations 
1.  Condition of fur Normal 
2.  Skin Normal 
3.  Subcutaneous swelling Nil 
4.  Eyes dullness Nil 
5.  Breathing abnormalities Nil 
6.  Food intake Normal 
7.  Colour and consistency of faeces Normal 
8.  Alertness Normal 
9.  Convulsions Not observed 
10.  Body temperature Normal 
11.  Body weight No specific change 
12.  Grooming Absent 
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6.5 INVITRO ANTI-ARTHRITIC ACTIVITY 
6.5.1 Body weight 
Table 13: Body weight changes 
GROUP 
BODY WEIGHT (g) 
1
st
 DAY 7
th
 DAY 14
th
 DAY 21
st
 DAY 
Group I 
(Normal control) 
170.16 
±0.87 
174.5±0.61 182.0±0.57 188.33±0.49 
Group 
II(Disease 
control) 
171.17± 
1.078 
161.67±0.67
### 
152.50±0.96
### 
154.83±0.79
### 
Group 
III(standard 
group) 
169.33±1.23 165.67±0.96
*** 
168.83±0.70
*** 
171.33±1.05
*** 
Group IV(Low 
dose test group 
250mg/kg) 
 
169.83±1.11 167.50±0.92
** 
170.83±0.79
*** 
173.83±0.87
*** 
Group V(High  
dose test 
group500mg/kg) 
 
169.33±0.88 166.83±0.83
*** 
171.33±1.43
*** 
173.5±0.96
*** 
Values are expressed as Mean ± SEM(n=6) 
###
p<0.001 compared with normal control 
***
p<0.001 compared with disease control 
**
p<0.01 compared with disease control 
  
 From table 13, it can be seen that, On day 1( before injection of CFA) no 
significant difference in body weight between normal control and  Groups 
II,III,IV,V.  
 On Day 7 there was a significant (p<0.001) decrease in the body weight in 
disease control rats when compared to the normal control rats. Treatment with 
Nimbadi churna at the dose of 250 mg/kg and 500mg/kg and Methotrexate (1mg/kg) 
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showed significant (p<0.001,p<0.01 and p<0.001 for Group III,IV,V respectively )  
increase in body weight when compared with the disease control group. 
 On Day 14 there was a significant (p<0.001) decrease in the body weight in 
disease control rats when compared to the normal control rats. Treatment with 
Nimbadi churna at the dose of 250 mg/kg and 500mg/kg  and Methotrexate 
(1mg/kg) showed significant (p<0.001,p<0.001and p<0.001 for Group III,IV,V 
respectively ) increase in body weight when compared with the disease control 
group. 
 On Day 21 there was a significant (p<0.001) decrease in the body weight in 
disease control rats when compared to the normal control rats. Treatment with 
Nimbadi churna at the dose of 250 mg/kg and 500mg/kg and Methotrexate (1mg/kg) 
showed significant (p<0.001,p<0.001and p<0.001 for Group III,IV,V respectively ) 
increase in body weight when compared with the disease control group. 
Fig: 6  Body weight 
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6.5.2 Paw volume 
Table 14: Paw volume 
GROUP 
PAW VOLUME (ml) 
1
st
 DAY 7
th
 DAY 14
th
 DAY 21
st
 DAY 
Group I 
(Normal 
control) 
0.010±0.001 0.010±0.001 0.010±0.001 0.012±0.001 
Group 
II(Disease 
control) 
0.011±0.001 0.040±0.002
### 
0.039±0.002
### 
0.037±0.004
### 
Group 
III(standard 
group) 
0.012±0.001 0.031±0.001
** 
0.025±0.001
*** 
0.020±0.001
*** 
Group IV(Low 
dose test 
group) 
 
0.013±0.001 0.033±0.002
* 
0.030±0.002
** 
0.025±0.001
*** 
Group V(High  
dose test 
group) 
 
0.012±0.001 0.032±0.002
** 
0.025±0.001
*** 
0.016±0.001
*** 
Values are expressed as Mean ± SEM(n=6) 
###
p<0.001 compared with normal control 
***
p<0.001 compared with disease control 
**
p<0.01 compared with disease control 
*
p<0.05 compared with disease control 
 
 From table 14, it can be seen that, On day 1(before injection of CFA) no 
significant difference in paw volume between normal control and Groups 
II,III,IV,V. 
 On Day 7 there was a significant (p<0.001) increase in the paw volume in 
disease control rats when compared to the normal control rats. Treatment with 
Nimbadi churna at the dose of 250 mg/kg and 500mg/kg and Methotrexate (1mg/kg) 
showed significant (p<0.01,p<0.05 and p<0.01 for Group III,IV,V respectively )  
reduction in rat paw edema volume when compared with the disease control group. 
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 On Day 14 there was a significant (p<0.001) increase in the paw volume in 
disease control rats when compared to the normal control rats. Treatment with 
Nimbadi churna at the dose of 250 mg/kg and 500mg/kg and Methotrexate (1mg/kg) 
showed significant (p<0.001,p<0.01and p<0.001 for Group III,IV,V respectively )  
reduction in rat paw 
edema volume when compared with the disease control group. 
 On Day 21 ,there was a significant (p<0.001) increase in the paw volume in 
disease control rats when compared to the normal control rats. Treatment with 
Nimbadi churna  at the dose of 250 mg/kg and 500mg/kg  and Methotrexate 
(1mg/kg) showed significant (p<0.001, p<0.001and p<0.001 for Group III,IV,V 
respectively )  reduction in rat paw 
edema volume when compared with the disease control group. 
Fig 7: Paw volume 
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6.5.3 Arthritic Score 
Table:15  Arthritic Score 
Group 
Group I 
(Normal 
control) 
Group 
II(Disease 
control) 
Group 
III(standard 
group) 
Group 
IV(Low dose 
test group) 
Group 
V(High  
dose test 
group) 
13
th
 
day 
00.00±0.00 4.67±0.33
### 
3.00±0.26
*** 
3.167±0.31
** 
2.83±0.31
*** 
21
st
 
day 
00.00±0.00 4.17±0.4
### 
1.83±0.167
*** 
1.667±0.21
*** 
1.5±0.22
*** 
Values are expressed as Mean ± SEM(n=6) 
###
p<0.001 compared with normal control 
***
p<0.001 compared with disease control 
**
p<0.01 compared with disease control 
  
 From table 15, it can be seen that, On day 13, there was a significant 
(p<0.001) difference in the arthritic score of  disease control rats when compared to 
the normal control rats. Treatment with Nimbadi churna at the dose of 250 mg/kg 
and 500mg/kg  and Methotrexate (1mg/kg) showed significant(p<0.001,p<0.01 and 
p<0.001 for Group III,IV,V respectively ) difference in arthritic score when 
compared with the disease control group. 
 On Day 21 there was a significant (p<0.001) ) difference in arthritic score in 
disease control rats when compared to the normal control rats. Treatment with 
Nimbadi churna at the dose of 250 mg/kg and 500mg/kg and Methotrexate (1mg/kg) 
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showed significant (p<0.001,p<0.001and p<0.001 for Group III,IV,V respectively ) 
difference in arthritic score when compared with the disease control group. 
Fig 8 : Arthritic Score 
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6.5.4 Haematological Parameters 
Table:16 Haematological Parameters 
GROUP RBC(10
6
cells/mm
3
) 
WBC 
(10
3
cells/mm
3
) 
Hb (g/dl) 
Group I 
(Normal control) 
7.47±0.29 5.22±0.3 13.51±0.22 
Group II 
(Disease control) 
5.16±0.13
### 
11.05±0.5
### 
10.52±0.51
### 
Group III 
(standard group) 
6.9±0.17
*** 
6.76±0.17
*** 
13.08±0.33
*** 
Group IV 
(Low dose test group) 
6.38±0.23
** 
9.12±0.34
** 
12.53±0.27
** 
Group V 
(High  dose test group) 
7.03±0.26
*** 
6.04±0.36
*** 
13.21±0.46
*** 
Values are expressed as Mean ± SEM(n=6) 
###
p<0.001 compared with normal control 
***
p<0.001 compared with disease control 
**
p<0.01 compared with disease control 
  
 From the table 16 , it can be seen that On Day 21, there was a significant 
(p<0.001) decrease in the RBC& Hb  count in disease control rats when compared to 
the normal control rats. Whereas treatment with Nimbadi churna at the dose of 250 
mg/kg and 500mg/kg  and Methotrexate (1mg/kg) showed significant increase in the 
RBC 7 Hb  count when compared with the disease control group. 
 On Day 21, there was a significant (p<0.001) increase in the WBC count in 
disease control rats when compared to the normal control rats. Treatment with 
Nimbadi churna at the dose of 250 mg/kg and 500mg/kg and Methotrexate (1mg/kg) 
showed significant (p<0.001, p<0.01 and p<0.001 for Group III,IV,V respectively )  
decrease in the WBC count when compared with the disease control group. 
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Fig 9: Effect of Nimbadi churna on RBC count 
 
Fig 10: Effect of Nimbadi churna on WBC count 
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Fig 11: Effect of Nimbadi churna on Hb count 
 
6.5.5 Serological Parameter 
Table:17 Serological Parameter 
Group 
Group I 
(Normal 
control) 
Group II 
(Disease 
control) 
GroupIII 
(standard 
group) 
Group IV 
(Low dose 
test group) 
Group V   
(High  dose test 
group) 
 
RF value 
(IU/ml) 
0.167±0.19 19.93±0.3
### 
4.61±0.16
*** 
8.97±0.18
*** 
5.16±0.21
*** 
Values are expressed as Mean ± SEM(n=6) 
###
p<0.001 compared with normal control 
***
p<0.001 compared with disease control 
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Fig 12: Serological Parameter 
 
  
 Rheumatoid factor (RF) is an antibody found with disease condition. It is one 
of several criteria used in diagnosing RA. From the table 17, it can be seen that On 
Day 21, there was a significant (p<0.001) increase in the rheumatoid factor in 
disease control rats when compared to the normal control rats. Treatment with 
Nimbadi churna at the dose of 250 mg/kg and 500mg/kg  and Methotrexate 
(1mg/kg) showed significant (p<0.001, p<0.001and p<0.001 for Group III,IV,V 
respectively )  reduction in rheumatoid factor when compared with the Disease 
control group. 
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6.5.6 Photographic representation of left hind paw of rats          
              Fig 13 : Photographic representation of left hind paw of rats on 21
st
 day 
 
 
  
a) Normal control b) Disease control 
  
c) Standard Group 
 
d) Low dose Nimbadi churna 
 
e) High Dose Nimbadi churna 
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 6.5.6 Histopathology 
 
 
 
  
a) Normal control b) Disease control 
  
c) Standard Group d) Low dose Nimbadi churna 
 
e) High Dose Nimbadi churna 
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(a) Joints in normal control group showed normal joint structure, no cartilage 
destruction. 
(b) Disease control showed cartilage destruction along with destruction of joint 
space , pannus formation & sheats of acute inflammatory cell with granulatory tissue  
formation. 
 (c) Standard group showed significant improvement in joint structure when 
compared with disease control 
 (d) Test group low dose showed significant improvement in joint structure as 
compared to the disease control group  
(e) Test group high dose also showed significant improvement in joint structure as 
compared to the disease control group and intact synovial membrane. 
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7.DISCUSSION 
  In traditional medicine numerous plants are used as single drug or poly 
herbal formulations to treat arthritis and other inflammatory diseases. Among them 
more than 60 plants were tested for their anti-inflammatory and anti-arthritic 
activities and more than 50 isolated phytochemicals showed varying levels of anti-
inflammatory activity in experimental animal models. Currently More than 110 
plants are used in various poly herbal preparations to treat arthritis and related 
diseases in Ayurveda.
85 
7.1 STANDARDISATION OF NIMBADI CHURNA 
  In present study an attempt was made to standardize Nimbadi churna since 
standardization of herbal formulation is essential in order to assess the quality, 
purity, safety and efficacy of the drug.
8 
  The organoleptic properties of Nimbadi churna was evaluated and given in 
table7 .Various physico-chemical parameters like loss on drying ,ash value, acid-
insoluble ash, alcohol-soluble extractive, pH also been evaluated .  
  Among this total ash value indicates total amount of inorganic 
material present in the churnaIt helps to detect the contamination and adulteration 
like sand or unwanted part mixed with crude drug.
86,8
 and the acid insoluble ash 
value is an indicative of silicate impurities, which might have arisen due to improper 
washing of drug.
8 
  The loss on drying value obtained is an indicative of amount of 
moisture content present in the drug. The moisture content of drug should always 
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exist below the critical level because excess moisture or insufficient drying is 
responsible for spoilage of drug due to growth of microbes.
86 
  The alcohol soluble extractive value indicates the amount of active 
constituent in given quantity of churna when extracted.
8 
The pH value 
conventionally represents the acidity or alkalinity of an aqueous solution. In 
pharmacopoeial standards limits of PH have been provided for particular substances 
in which hydrogen-ion activity plays a major role in stability of substance.
86
 The 
values were given in table 8. The values obtained for Nimbadi churna has been 
found to be within limits. 
  Physical evaluation of Nimbadi was performed mainly to determine its flow 
property and the results obtained were given in table 9. As a general guide, powders 
with angle of repose greater than 50° have unsatisfactory flow properties, whereas 
minimal angle close to 25° correspond to very good flow properties as well as the 
flow character of powder was categorized as fair if it exhibit carr‘s index value and 
Hauner‘s ratio in the range of 16-20% and 1.19-1.25 respectively.48 
  The angle of repose, compressibility index (%) and hausner‘s ratio of 
Nimbadi churna was found to be 27°61’ 0.65, 18.39 1.48, 1.23      
respectively. From the results obtained it can be concluded that Nimbadi churna 
possess good flow property. 
  The practical yield of Nimbadi churna on maceration using methanol as a 
solvent was found to be 29.2% w/w. 
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7.2 PHYTOCHEMICAL ANALYSIS OF NIMBADI CHURNA 
  Phytochemical evaluation of methanolic extract of Nimbadi churna 
showed the presence of alkaloids, flavonoids, reducing sugar, Glycoside, phenolic 
compound, Tannins, Saponin, Protein and amino acids,Terpenoids. Previous 
Pharmacological studies indicate that flavonoids and saponins were reported to 
possess  anti-inflammatory and antiarthritic activity.
87,88
  
7.3 IN VITRO ANTIOXIDANT ACTIVITY OF NIMBADI CHURNA 
  Invitro antioxidant activity of Nimbadi churna extract was evaluated 
by performing DPPH radical scavenging assay. It was observed that Nimbadi churna 
scavenge free radicals in a concentration dependent manner. The IC50 value of a 
compound is inversely related to its antioxidant capacity. A lower IC50 value 
indicates a stronger antioxidant activity of the compound.
89
 The values are depicted 
in the table 11 and the IC50 value of Nimbadi churna was found to be 565.4μg/ml, 
which is more or less similar to that of the standard (515.5μg/ml).   
7.4 ACUTE ORAL TOXICITY STUDY OF NIMBADI CHURNA 
   Acute oral toxicity study of Nimbadi churna were performed 
according to the OECD-423 guidelines. The treatment of rats with Nimbadi churna 
did not produce any mortality at a dose of 2000mg/kg. There were no signs of 
toxicities which are depicted in table 12 ,and thus Nimbadi churna comes under the 
category of Class 5 or unclassified and the LD50 was considered to be >2000 mg/kg. 
7.5 INVIVO ANTIARTHRITIC ACTIVITY 
  In the present study the anti-arthritic activity of Nimbadi churna was 
evaluated by Complete Freund‘s Adjuvant induced arthritis. CFA-induced 
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polyarthritis is associated with an immune mediated inflammatory reaction and the 
rat is unique in developing polyarthritis after CFA treatment. It is the most widely 
used chronic test model in which the clinical and pathological changes are 
comparable with those seen in human rheumatoid arthritis. . 
  Normally in rheumatoid arthritis body weight decrease due to 
infectious condition. (Somasundaran et al., 1983) suggest that absorption of 14C- 
glucose and 14C-leucine in rat‘s intestine have been reduced during inflammatory 
disorders
90
 and also  (Yoshizaki et al., 1998; Rall and Roubenoff, 2004) states that 
weight loss is one among the common features in rheumatoid arthritis and these are 
thought to be due to increased cytokine production which increases resting 
metabolic rate and protein breakdown as well as poor appetite.
91,92 
 In present study, changes in body weight were evaluated 0n 1
st
 ,7
th
 ,14
th
 and 
21
st
 days. Results showed  a significant reduction in body weight was observed in 
disease control when compared with normal control. But animals in Nimbadi churna 
and Methotrexate  treated groups body weight  decreased initially but after 14 days 
body weight was fond to be increased. The increased body weight during treatment 
of standard drug, Nimbadi churna extracts may be due to the restoration of 
absorption capacity of intestine. HEAC improved the weight gain pattern in the 
treated arthritic rats as observed in this study suggest that this could be due to 
improvement in the arthritic state of the rats 
 The determination of paw swelling is apparently a simple, sensitive and 
quick procedure for evaluating the degree of inflammation and the therapeutic 
effects of drugs. Chronic inflammation involves the release of number of mediators 
like cytokines (IL-1B and TNF- ), interferon‘s these mediators are responsible for 
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the pain, destruction of bone and cartilage that can lead to severe disability. In our 
present study both high and low dose of Nimbadi churna and Methotrexate treated 
groups showed significant reduction in the swelling of the paws when compared 
with disease control group, which is in concordance with the results previously 
reported by (S. Tripathy et al.,2009).
93
 Though the actual mechanism of 
suppressing inflammation is not known , it may be due to the presence of alkaloids 
and flavonoids in the Nimbadi churna extract because of its ability to suppress 
inflammation and its antioxidant activity. 
 Arthritic index is summation of scores obtained by giving ranks to extent of 
inflammation, formation of nodules and extent of spread of disease at non injectable 
sites.It indicates the secondary immune response to administration of CFA.
34
 In 
present study arthritic index was calculated on 13
th
 and 21
st
 days and the results 
showed that arthritic index was significantly reduced in Nimbadi churna extract and 
Methotrexate 1mg/kg treated groups as compared with diaease control group. 
  Anemia is the major sign of rheumatoid arthritis. The decrease in Hb and 
RBC level in arthritic rats mainly occur due to the decrease in  plasma iron level. 
The decrease in plasma iron concentration was in turn due to bone marrow changes 
in arthritis.
94
  In present study Hb & RBC count of disease control shows significant 
reduction when compared with normal control but treatment with  different doses 
(250mg/kg and 500mg/kg) of Nimbadi churna and Methotrexate shows significant 
increase in Hb & RBC count when compared with disease control. 
  Under normal conditions, the white blood cell count will be between 5,000 
to10, 000. A high white blood cell count could suggest inflammation, which can be 
due to rheumatoid arthritis (RA). In present study, on 21
st
 day disease control group 
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shows significant increase in WBC count when compared with normal control but 
treatment with different doses (250mg/kg and 500mg/kg) of Nimbadi churna and 
Methotrexate shows significant decrease in WBC count when compared with 
disease control. Significant decrease in the WBC count indicates that the migration 
of leukocytes to the inflamed area was significantly suppressed by Nimbadi 
churna extract.
94
  
  Rheumatoid factor (RF) is an autoantibody (antibody directed against an 
organism's own tissues) that is most relevant in rheumatoid arthritis. It is defined as 
an antibody against the Fc portion of IgG. RF and IgG join to form immune 
complexes that contribute to the disease process.
34
 In present study  there was a 
significant increase in serum RF value of disease control animals as compared to 
normal control animals. But treatment with Nimbadi churna and methotrexate 
showed significant reduction in RF value when compared with disease control 
group. 
  In present study histopathology of synovial joints of disease control showed 
higher cartilage destruction along with destruction of joint space & Sheaths of acute 
inflammatory cell with granulatory tissue  formation. Treatment with low dose 
Nimbadi churna showed significant improvement in joint structure , Whereas 
treatment with high dose Nimbadi churna showed intact synovial membrane. 
Methotrexate (1mg/kg) group  showed Showed significant improvement in joint 
structure when compared with disease control. 
  From all the above observations it can be concluded that Nimbadi churna 
possess anti-arthritic activity to greater extent. 
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8.CONCLUSION 
 India has a rich heritage of traditional medicine constituting with its different 
components like Ayurveda, Siddha and Unani. In the last few decades, there has 
been an exponential growth in the field of ayurvedic medicine. From the study it has 
been concluded that Nimbadi churna, which is extensively used in treating psoriasis 
and other many other skin diseases, has significant anti-arthritic activity at a dose of 
500mg/kg. The methanolic extract of Nimbadi churna also found to exhibit 
significant DPPH radical scavenging activity ,which indicates the anti-oxidant 
activity of Nimbadi churna. This study validates the ayurvedic  claim of Nimbadi 
churna as an anti-arthritic agent. 
Further, in-vivo studies are needed to explore the possible mechanism of 
action of isolated compounds derived from Nimbadi churna in treating arthritis. 
This claim can be further strengthened by carrying out a systemic clinical 
study using Nimbadi churna in arthritic patients.  
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